Pricing Log in Create free account
Friday 6 November 2026 Export CGON’s income statement to Excel — free account

CG Oncology, Inc.

CGON Healthcare Biotechnology

CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.

Revenue
−3.72%
EPS
−12.3%
Free cash flow
−67.6%
Total debt
0.00%

Quarter to September 2026, against a year earlier

76.08 11.28 +17.41%
Market cap
$5.7B
P/E
0.0×
Fwd P/E
−19.5×
Dividend yield
—
F-score
2/9
Altman Z
49.04
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

CG Oncology, Inc. (CGON) EBITDA

Alert me on EBITDA

CG Oncology, Inc.'s EBITDA for fiscal 2025 was −$190.3M, compared with −$119.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$250.7M. EBITDA has fallen for 3 consecutive fiscal years. CG Oncology, Inc. ranks 535th of 594 Biotechnology companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 −$190.3M —
FY2024 −$119.6M —
FY2023 −$58.3M —
FY2022 −$35.2M —

Quarterly newest first

Period EBITDA Change
Jun 2026 −$87.2M —
Mar 2026 −$63.9M —
Dec 2025 −$46.9M —
Sep 2025 −$52.7M —
10 more quarters

EBITDA against peers

Company EBITDA
PTCT PTC Therapeutics, Inc. compare $191.8M
LGND Ligand Pharmaceuticals Incorporated compare $57.3M
MANE Veradermics Incorporated compare −$88.4M
BLTE Belite Bio, Inc. Sponsored ADR compare −$118.6M
KOD Kodiak Sciences Inc. compare −$220.8M
CGON CG Oncology, Inc. −$250.7M
SRRK Scholar Rock Holding Corporation compare −$405.8M
IMVT Immunovant, Inc. compare −$565.6M
MIRM Mirum Pharmaceuticals, Inc. compare −$867.1M

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on CGON